CEQUA (cyclosporine) by Fosun Pharma is calcineurin inhibitors [moa]. First approved in 2018.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
CEQUA is a cyclosporine ophthalmic solution approved in 2018 for treating dry eye disease by suppressing local immune-mediated inflammation through calcineurin inhibition. It is administered as eye drops to patients with moderate-to-severe dry eye who have failed conventional therapies. The drug works by inhibiting T-cell activation and reducing pro-inflammatory cytokine production at the ocular surface.
Mature product in peak lifecycle phase with stable Medicare utilization; commercial team size likely stable with focus on market penetration and retention.
Calcineurin Inhibitors
Calcineurin Inhibitor Immunosuppressant
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
Cyclosporine In Takotsubo Syndrome
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.
Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA
Worked on CEQUA at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CEQUA offers a stable career trajectory in a niche ophthalmology segment with mature commercial operations and strong patent protection. The product's peak lifecycle stage and zero competitive threats create a low-risk, established-market environment ideal for professionals seeking market penetration and operational excellence rather than high-growth excitement.